Drug Profile


Alternative Names: Anamorelin HCl; Anamorelin hydrochloride; ONO-7643; RC-1291; ST-1291

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Helsinn Therapeutics; Ono Pharmaceutical
  • Class Appetite stimulants; Piperidines; Small molecules
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Anorexia; Cachexia
  • Phase II Fatigue

Most Recent Events

  • 19 May 2017 CHMP adopts negative opinion for approval of anamorelin for Anorexia and Cachexia in European Union
  • 08 Feb 2017 Phase-II clinical trials in cancer Fatigue in USA (PO) (NCT03035409)
  • 26 Jan 2017 M.D. Anderson Cancer Center and Helsinn Healthcare plan a phase II trial for Cachexia in USA (PO) (NCT03035409)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top